Printer Friendly

Pall Corporation announces expansion of Life Sciences manufacturing center in New York; facility doubles capacity for tangential flow filtration systems. (Industry News).

In a move to enhance its manufacturing of Tangential Flow Filtration (TFF) membranes and cassettes for biopharmaceutical applications, Pall Corporation has announced an expansion of its Life Sciences filter manufacturing facility in Hauppauge, New York. The ISO-9002-certified facility will focus exclusively on the manufacture and assembly of membrane TFF systems, and on blood and viral filtration membranes. The 75,000 square foot plant has more than 100 employees, an increase in staff of nearly 50 percent. The official opening of the facility was Tuesday, April 16, at 2:00 p.m.

Nobel laureate James D. Watson, Ph.D., President of Cold Spring Harbor Laboratory and discoverer of the structure of DNA, gave the keynote address. He was joined by New York's Lt. Governor Mary Donohue and other government officials. Daniel Vellom, Ph.D., Associate Director of Purification Development at Acambis Inc. spoke on "Challenges of Manufacturing Live Viral Vaccines". Acambis, a biopharmaceutical company, is developing a new smallpox vaccine.

"The newly designed facility for tangential flow filtration membranes and cassettes manufacturing is a demonstration of Pall's commitment to the biopharmaceutical community. Tangential flow filtration systems are a key component of our Life Sciences business, and will continue to be so in the years to come," said Ed Hoare, President of Pall Life Sciences' BioPharmaceuticals Division.

TFF membranes and cassettes are used to improve the quality of biopharmaceutical products and productivity of the process. "We anticipate double-digit growth in sales for these important products over the next three to five years," Hoare added.

The state-of-the art facility performs all TFF membrane and cassette manufacturing under one roof, doubling Pall's production capacity. A majority of the manufacturing and assembly is performed in glassed areas that enable easy observation for customer inspection and auditing. Encompassing all aspects of manufacturing from beginning to end in one facility enables Pall to control the process more efficiently, and ensure consistent product quality, traceability and reduced lead times.

"Pall's customers will gain from our streamlined manufacturing and improved process control," says Leonard L. Krakauer, President of the Hauppauge facility. "Our operations meet the strictest quality standards and qualify for use in the most rigorous biopharmaceutical GMP applications," he added.

More Info: www.pall.com
COPYRIGHT 2002 Advantage Business Media
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Pharmaceutical Processing
Date:May 1, 2002
Words:367
Previous Article:Upgraded online version of the USP-NF now available. (Industry News).
Next Article:TEK Supply, Inc., stainless pipe & fittings and stainless pipe, fittings & metals consolidate to form TEK. (Industry News).
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters